Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 229

1.

Response-adapted intensification with cyclophosphamide, bortezomib, and dexamethasone versus no intensification in patients with newly diagnosed multiple myeloma (Myeloma XI): a multicentre, open-label, randomised, phase 3 trial.

Jackson GH, Davies FE, Pawlyn C, Cairns DA, Striha A, Collett C, Waterhouse A, Jones JR, Kishore B, Garg M, Williams CD, Karunanithi K, Lindsay J, Wilson JN, Jenner MW, Cook G, Kaiser MF, Drayson MT, Owen RG, Russell NH, Gregory WM, Morgan GJ; UK NCRI Haematological Oncology Clinical Studies Group.

Lancet Haematol. 2019 Oct 14. pii: S2352-3026(19)30167-X. doi: 10.1016/S2352-3026(19)30167-X. [Epub ahead of print]

2.

Transcriptome-wide association study of multiple myeloma identifies candidate susceptibility genes.

Went M, Kinnersley B, Sud A, Johnson DC, Weinhold N, Försti A, van Duin M, Orlando G, Mitchell JS, Kuiper R, Walker BA, Gregory WM, Hoffmann P, Jackson GH, Nöthen MM, da Silva Filho MI, Thomsen H, Broyl A, Davies FE, Thorsteinsdottir U, Hansson M, Kaiser M, Sonneveld P, Goldschmidt H, Stefansson K, Hemminki K, Nilsson B, Morgan GJ, Houlston RS.

Hum Genomics. 2019 Aug 20;13(1):37. doi: 10.1186/s40246-019-0231-5.

3.

An acquired high-risk chromosome instability phenotype in multiple myeloma: Jumping 1q Syndrome.

Sawyer JR, Tian E, Walker BA, Wardell C, Lukacs JL, Sammartino G, Bailey C, Schinke CD, Thanendrarajan S, Davies FE, Morgan GJ, Barlogie B, Zangari M, van Rhee F.

Blood Cancer J. 2019 Aug 9;9(8):62. doi: 10.1038/s41408-019-0226-4.

4.

Lack of Spleen Signal on Diffusion Weighted MRI is associated with High Tumor Burden and Poor Prognosis in Multiple Myeloma: A Link to Extramedullary Hematopoiesis?

Rasche L, Kumar M, Gershner G, Samant R, Van Hemert R, Heidemeier A, Lapa C, Bley T, Buck A, McDonald J, Hillengass J, Epstein J, Thanendrarajan S, Schinke C, van Rhee F, Zangari M, Barlogie B, Davies FE, Morgan GJ, Weinhold N.

Theranostics. 2019 Jul 9;9(16):4756-4763. doi: 10.7150/thno.33289. eCollection 2019.

5.

Microhomology-mediated end joining drives complex rearrangements and over expression of MYC and PVT1 in multiple myeloma.

Mikulasova A, Ashby C, Tytarenko RG, Qu P, Rosenthal A, Dent JA, Ryan KR, Bauer MA, Wardell CP, Hoering A, Mavrommatis K, Trotter M, Deshpande S, Yaccoby S, Tian E, Keats J, Auclair D, Jackson GH, Davies FE, Thakurta A, Morgan GJ, Walker BA.

Haematologica. 2019 Jun 20. pii: haematol.2019.217927. doi: 10.3324/haematol.2019.217927. [Epub ahead of print]

6.

INSIGHT MM: a large, global, prospective, non-interventional, real-world study of patients with multiple myeloma.

Costello C, Davies FE, Cook G, Vela-Ojeda J, Omel J, Rifkin RM, Berdeja J, Puig N, Usmani SZ, Weisel K, Zonder JA, Terpos E, Spencer A, Leleu X, Boccadoro M, Thompson MA, Romanus D, Stull DM, Hungria V.

Future Oncol. 2019 May;15(13):1411-1428. doi: 10.2217/fon-2019-0013. Epub 2019 Feb 28.

7.

Binding to an Unusual Inactive Kinase Conformation by Highly Selective Inhibitors of Inositol-Requiring Enzyme 1α Kinase-Endoribonuclease.

Colombano G, Caldwell JJ, Matthews TP, Bhatia C, Joshi A, McHardy T, Mok NY, Newbatt Y, Pickard L, Strover J, Hedayat S, Walton MI, Myers SM, Jones AM, Saville H, McAndrew C, Burke R, Eccles SA, Davies FE, Bayliss R, Collins I.

J Med Chem. 2019 Mar 14;62(5):2447-2465. doi: 10.1021/acs.jmedchem.8b01721. Epub 2019 Mar 5.

8.

Poor overall survival in hyperhaploid multiple myeloma is defined by double-hit bi-allelic inactivation of TP53.

Ashby C, Tytarenko RG, Wang Y, Weinhold N, Johnson SK, Bauer M, Wardell CP, Schinke C, Thanendrarajan S, Zangari M, van Rhee F, Davies FE, Sawyer JR, Morgan GJ, Walker BA.

Oncotarget. 2019 Jan 22;10(7):732-737. doi: 10.18632/oncotarget.26589. eCollection 2019 Jan 22.

9.

A clinical prediction model for outcome and therapy delivery in transplant-ineligible patients with myeloma (UK Myeloma Research Alliance Risk Profile): a development and validation study.

Cook G, Royle KL, Pawlyn C, Hockaday A, Shah V, Kaiser MF, Brown SR, Gregory WM, Child JA, Davies FE, Morgan GJ, Cairns DA, Jackson GH.

Lancet Haematol. 2019 Mar;6(3):e154-e166. doi: 10.1016/S2352-3026(18)30220-5. Epub 2019 Feb 6.

10.

Clonal evolution in myeloma: the impact of maintenance lenalidomide and depth of response on the genetics and sub-clonal structure of relapsed disease in uniformly treated newly diagnosed patients.

Jones JR, Weinhold N, Ashby C, Walker BA, Wardell C, Pawlyn C, Rasche L, Melchor L, Cairns DA, Gregory WM, Johnson D, Begum DB, Ellis S, Sherborne AL, Cook G, Kaiser MF, Drayson MT, Owen RG, Jackson GH, Davies FE, Greaves M, Morgan GJ; NCRI Haemato-Oncology CSG.

Haematologica. 2019 Jul;104(7):1440-1450. doi: 10.3324/haematol.2018.202200. Epub 2019 Feb 7.

11.

Author Correction: Identification of multiple risk loci and regulatory mechanisms influencing susceptibility to multiple myeloma.

Went M, Sud A, Försti A, Halvarsson BM, Weinhold N, Kimber S, van Duin M, Thorleifsson G, Holroyd A, Johnson DC, Li N, Orlando G, Law PJ, Ali M, Chen B, Mitchell JS, Gudbjartsson DF, Kuiper R, Stephens OW, Bertsch U, Broderick P, Campo C, Bandapalli OR, Einsele H, Gregory WA, Gullberg U, Hillengass J, Hoffmann P, Jackson GH, Jöckel KH, Johnsson E, Kristinsson SY, Mellqvist UH, Nahi H, Easton D, Pharoah P, Dunning A, Peto J, Canzian F, Swerdlow A, Eeles RA, Kote-Jarai Z, Muir K, Pashayan N; PRACTICAL consortium, Nickel J, Nöthen MM, Rafnar T, Ross FM, da Silva Filho MI, Thomsen H, Turesson I, Vangsted A, Andersen NF, Waage A, Walker BA, Wihlborg AK, Broyl A, Davies FE, Thorsteinsdottir U, Langer C, Hansson M, Goldschmidt H, Kaiser M, Sonneveld P, Stefansson K, Morgan GJ, Hemminki K, Nilsson B, Houlston RS.

Nat Commun. 2019 Jan 10;10(1):213. doi: 10.1038/s41467-018-08107-8.

12.

Genetic correlation between multiple myeloma and chronic lymphocytic leukaemia provides evidence for shared aetiology.

Went M, Sud A, Speedy H, Sunter NJ, Försti A, Law PJ, Johnson DC, Mirabella F, Holroyd A, Li N, Orlando G, Weinhold N, van Duin M, Chen B, Mitchell JS, Mansouri L, Juliusson G, Smedby KE, Jayne S, Majid A, Dearden C, Allsup DJ, Bailey JR, Pratt G, Pepper C, Fegan C, Rosenquist R, Kuiper R, Stephens OW, Bertsch U, Broderick P, Einsele H, Gregory WM, Hillengass J, Hoffmann P, Jackson GH, Jöckel KH, Nickel J, Nöthen MM, da Silva Filho MI, Thomsen H, Walker BA, Broyl A, Davies FE, Hansson M, Goldschmidt H, Dyer MJS, Kaiser M, Sonneveld P, Morgan GJ, Hemminki K, Nilsson B, Catovsky D, Allan JM, Houlston RS.

Blood Cancer J. 2018 Dec 21;9(1):1. doi: 10.1038/s41408-018-0162-8.

13.

Toward personalized treatment in multiple myeloma based on molecular characteristics.

Pawlyn C, Davies FE.

Blood. 2019 Feb 14;133(7):660-675. doi: 10.1182/blood-2018-09-825331. Epub 2018 Dec 26. Review.

14.

Combination of flow cytometry and functional imaging for monitoring of residual disease in myeloma.

Rasche L, Alapat D, Kumar M, Gershner G, McDonald J, Wardell CP, Samant R, Van Hemert R, Epstein J, Williams AF, Thanendrarajan S, Schinke C, Bauer M, Ashby C, Tytarenko RG, van Rhee F, Walker BA, Zangari M, Barlogie B, Davies FE, Morgan GJ, Weinhold N.

Leukemia. 2019 Jul;33(7):1713-1722. doi: 10.1038/s41375-018-0329-0. Epub 2018 Dec 20.

15.

Lenalidomide maintenance versus observation for patients with newly diagnosed multiple myeloma (Myeloma XI): a multicentre, open-label, randomised, phase 3 trial.

Jackson GH, Davies FE, Pawlyn C, Cairns DA, Striha A, Collett C, Hockaday A, Jones JR, Kishore B, Garg M, Williams CD, Karunanithi K, Lindsay J, Jenner MW, Cook G, Russell NH, Kaiser MF, Drayson MT, Owen RG, Gregory WM, Morgan GJ; UK NCRI Haemato-oncology Clinical Studies Group.

Lancet Oncol. 2019 Jan;20(1):57-73. doi: 10.1016/S1470-2045(18)30687-9. Epub 2018 Dec 14.

16.

The genomic landscape of plasma cells in systemic light chain amyloidosis.

Boyle EM, Ashby C, Wardell CP, Rowczenio D, Sachchithanantham S, Wang Y, Johnson SK, Bauer MA, Weinhold N, Kaiser MF, Johnson DC, Jones JR, Pawlyn C, Proszek P, Schinke C, Facon T, Dumontet C, Davies FE, Morgan GJ, Walker BA, Wechalekar AD.

Blood. 2018 Dec 27;132(26):2775-2777. doi: 10.1182/blood-2018-08-872226. Epub 2018 Nov 16. No abstract available.

PMID:
30446495
17.

Mesenchymal stem cells gene signature in high-risk myeloma bone marrow linked to suppression of distinct IGFBP2-expressing small adipocytes.

Mehdi SJ, Johnson SK, Epstein J, Zangari M, Qu P, Hoering A, van Rhee F, Schinke C, Thanendrarajan S, Barlogie B, Davies FE, Morgan GJ, Yaccoby S.

Br J Haematol. 2019 Feb;184(4):578-593. doi: 10.1111/bjh.15669. Epub 2018 Nov 8.

PMID:
30408155
18.

Subclonal TP53 copy number is associated with prognosis in multiple myeloma.

Shah V, Johnson DC, Sherborne AL, Ellis S, Aldridge FM, Howard-Reeves J, Begum F, Price A, Kendall J, Chiecchio L, Savola S, Jenner MW, Drayson MT, Owen RG, Gregory WM, Morgan GJ, Davies FE, Houlston RS, Cook G, Cairns DA, Jackson G, Kaiser MF; National Cancer Research Institute Haematology Clinical Studies Group.

Blood. 2018 Dec 6;132(23):2465-2469. doi: 10.1182/blood-2018-06-857250. Epub 2018 Oct 29.

19.

Practical Considerations for Antibodies in Myeloma.

Laubach JP, van de Donk N, Davies FE, Mikhael J.

Am Soc Clin Oncol Educ Book. 2018 May 23;38:667-674. doi: 10.1200/EDBK_205443. Review.

PMID:
30231321
20.

Identification of multiple risk loci and regulatory mechanisms influencing susceptibility to multiple myeloma.

Went M, Sud A, Försti A, Halvarsson BM, Weinhold N, Kimber S, van Duin M, Thorleifsson G, Holroyd A, Johnson DC, Li N, Orlando G, Law PJ, Ali M, Chen B, Mitchell JS, Gudbjartsson DF, Kuiper R, Stephens OW, Bertsch U, Broderick P, Campo C, Bandapalli OR, Einsele H, Gregory WA, Gullberg U, Hillengass J, Hoffmann P, Jackson GH, Jöckel KH, Johnsson E, Kristinsson SY, Mellqvist UH, Nahi H, Easton D, Pharoah P, Dunning A, Peto J, Canzian F, Swerdlow A, Eeles RA, Kote-Jarai Z, Muir K, Pashayan N, Nickel J, Nöthen MM, Rafnar T, Ross FM, da Silva Filho MI, Thomsen H, Turesson I, Vangsted A, Andersen NF, Waage A, Walker BA, Wihlborg AK, Broyl A, Davies FE, Thorsteinsdottir U, Langer C, Hansson M, Goldschmidt H, Kaiser M, Sonneveld P, Stefansson K, Morgan GJ, Hemminki K, Nilsson B, Houlston RS; PRACTICAL consortium.

Nat Commun. 2018 Sep 13;9(1):3707. doi: 10.1038/s41467-018-04989-w. Erratum in: Nat Commun. 2019 Jan 10;10(1):213.

21.

Serum free light chain levels and renal function at diagnosis in patients with multiple myeloma.

Yadav P, Cockwell P, Cook M, Pinney J, Giles H, Aung YS, Cairns D, Owen RG, Davies FE, Jackson GH, Child JA, Morgan GJ, Drayson MT.

BMC Nephrol. 2018 Jul 13;19(1):178. doi: 10.1186/s12882-018-0962-x.

22.

Quality of life during and following sequential treatment of previously untreated patients with multiple myeloma: findings of the Medical Research Council Myeloma IX randomised study.

Royle KL, Gregory WM, Cairns DA, Bell SE, Cook G, Owen RG, Drayson MT, Davies FE, Jackson GH, Morgan GJ, Child JA.

Br J Haematol. 2018 Sep;182(6):816-829. doi: 10.1111/bjh.15459. Epub 2018 Jul 9.

23.

MAFb protein confers intrinsic resistance to proteasome inhibitors in multiple myeloma.

Qiang YW, Ye S, Huang Y, Chen Y, Van Rhee F, Epstein J, Walker BA, Morgan GJ, Davies FE.

BMC Cancer. 2018 Jul 6;18(1):724. doi: 10.1186/s12885-018-4602-4.

24.

Identification of novel mutational drivers reveals oncogene dependencies in multiple myeloma.

Walker BA, Mavrommatis K, Wardell CP, Ashby TC, Bauer M, Davies FE, Rosenthal A, Wang H, Qu P, Hoering A, Samur M, Towfic F, Ortiz M, Flynt E, Yu Z, Yang Z, Rozelle D, Obenauer J, Trotter M, Auclair D, Keats J, Bolli N, Fulciniti M, Szalat R, Moreau P, Durie B, Stewart AK, Goldschmidt H, Raab MS, Einsele H, Sonneveld P, San Miguel J, Lonial S, Jackson GH, Anderson KC, Avet-Loiseau H, Munshi N, Thakurta A, Morgan GJ.

Blood. 2018 Aug 9;132(6):587-597. doi: 10.1182/blood-2018-03-840132. Epub 2018 Jun 8. Erratum in: Blood. 2018 Sep 27;132(13):1461.

25.

The presence of large focal lesions is a strong independent prognostic factor in multiple myeloma.

Rasche L, Angtuaco EJ, Alpe TL, Gershner GH, McDonald JE, Samant RS, Kumar M, Van Hemert R, Epstein J, Deshpande S, Tytarenko R, Yaccoby S, Hillengass J, Thanendrarajan S, Schinke C, van Rhee F, Zangari M, Walker BA, Barlogie B, Morgan GJ, Davies FE, Weinhold N.

Blood. 2018 Jul 5;132(1):59-66. doi: 10.1182/blood-2018-04-842880. Epub 2018 May 21.

26.

Kinase domain activation through gene rearrangement in multiple myeloma.

Morgan GJ, He J, Tytarenko R, Patel P, Stephens OW, Zhong S, Deshpande S, Bauer M, Weinhold N, Schinke C, Rasche L, Bailey M, Ali S, Ross J, Miller VA, Stephens P, Thanendrarajan S, Zangari M, van Rhee F, Mughal T, Davies FE, Walker BA.

Leukemia. 2018 Nov;32(11):2435-2444. doi: 10.1038/s41375-018-0108-y. Epub 2018 Mar 23.

27.

Treatment to suppression of focal lesions on positron emission tomography-computed tomography is a therapeutic goal in newly diagnosed multiple myeloma.

Davies FE, Rosenthal A, Rasche L, Petty NM, McDonald JE, Ntambi JA, Steward DM, Panozzo SB, van Rhee F, Zangari M, Schinke CD, Thanendrarajan S, Walker B, Weinhold N, Barlogie B, Hoering A, Morgan GJ.

Haematologica. 2018 Jun;103(6):1047-1053. doi: 10.3324/haematol.2017.177139. Epub 2018 Mar 22.

28.

The Pattern of Mesenchymal Stem Cell Expression Is an Independent Marker of Outcome in Multiple Myeloma.

Schinke C, Qu P, Mehdi SJ, Hoering A, Epstein J, Johnson SK, van Rhee F, Zangari M, Thanendrarajan S, Barlogie B, Davies FE, Yaccoby S, Morgan GJ.

Clin Cancer Res. 2018 Jun 15;24(12):2913-2919. doi: 10.1158/1078-0432.CCR-17-2627. Epub 2018 Mar 21.

29.

Loss of heterozygosity as a marker of homologous repair deficiency in multiple myeloma: a role for PARP inhibition?

Pawlyn C, Loehr A, Ashby C, Tytarenko R, Deshpande S, Sun J, Fedorchak K, Mughal T, Davies FE, Walker BA, Morgan GJ.

Leukemia. 2018 Jul;32(7):1561-1566. doi: 10.1038/s41375-018-0017-0. Epub 2018 Feb 2.

30.

HSF1 Is Essential for Myeloma Cell Survival and A Promising Therapeutic Target.

Fok JHL, Hedayat S, Zhang L, Aronson LI, Mirabella F, Pawlyn C, Bright MD, Wardell CP, Keats JJ, De Billy E, Rye CS, Chessum NEA, Jones K, Morgan GJ, Eccles SA, Workman P, Davies FE.

Clin Cancer Res. 2018 May 15;24(10):2395-2407. doi: 10.1158/1078-0432.CCR-17-1594. Epub 2018 Feb 1.

31.

Oncogenic RAC1 and NRAS drive resistance to endoplasmic reticulum stress through MEK/ERK signalling.

Bright MD, Clarke PA, Workman P, Davies FE.

Cell Signal. 2018 Apr;44:127-137. doi: 10.1016/j.cellsig.2018.01.004. Epub 2018 Jan 9.

32.

Is molecular remission the goal of multiple myeloma therapy?

Davies FE.

Hematology Am Soc Hematol Educ Program. 2017 Dec 8;2017(1):205-211. doi: 10.1182/asheducation-2017.1.205. Review.

33.

Cardiovascular complications of multiple myeloma in the elderly.

Mathur P, Thanendrarajan S, Paydak H, Vallurupalli S, Jambhekar K, Bhatti S, Schinke CD, Davies FE, Mehta JL.

Expert Rev Cardiovasc Ther. 2017 Dec;15(12):933-943. doi: 10.1080/14779072.2017.1409114. Epub 2017 Nov 27. Review.

PMID:
29164945
34.

Neutral tumor evolution in myeloma is associated with poor prognosis.

Johnson DC, Lenive O, Mitchell J, Jackson G, Owen R, Drayson M, Cook G, Jones JR, Pawlyn C, Davies FE, Walker BA, Wardell C, Gregory WM, Cairns D, Morgan GJ, Houlston RS, Kaiser MF.

Blood. 2017 Oct 5;130(14):1639-1643. doi: 10.1182/blood-2016-11-750612. Epub 2017 Aug 21.

35.

Spatial genomic heterogeneity in multiple myeloma revealed by multi-region sequencing.

Rasche L, Chavan SS, Stephens OW, Patel PH, Tytarenko R, Ashby C, Bauer M, Stein C, Deshpande S, Wardell C, Buzder T, Molnar G, Zangari M, van Rhee F, Thanendrarajan S, Schinke C, Epstein J, Davies FE, Walker BA, Meissner T, Barlogie B, Morgan GJ, Weinhold N.

Nat Commun. 2017 Aug 16;8(1):268. doi: 10.1038/s41467-017-00296-y.

36.

Anti-myeloma effects of ruxolitinib combined with bortezomib and lenalidomide: A rationale for JAK/STAT pathway inhibition in myeloma patients.

de Oliveira MB, Fook-Alves VL, Eugenio AIP, Fernando RC, Sanson LFG, de Carvalho MF, Braga WMT, Davies FE, Colleoni GWB.

Cancer Lett. 2017 Sep 10;403:206-215. doi: 10.1016/j.canlet.2017.06.016. Epub 2017 Jun 20.

PMID:
28645562
37.

Assessing the effect of obesity-related traits on multiple myeloma using a Mendelian randomisation approach.

Went M, Sud A, Law PJ, Johnson DC, Weinhold N, Försti A, van Duin M, Mitchell JS, Chen B, Kuiper R, Stephens OW, Bertsch U, Campo C, Einsele H, Gregory WM, Henrion M, Hillengass J, Hoffmann P, Jackson GH, Lenive O, Nickel J, Nöthen MM, da Silva Filho MI, Thomsen H, Walker BA, Broyl A, Davies FE, Langer C, Hansson M, Kaiser M, Sonneveld P, Goldschmidt H, Hemminki K, Nilsson B, Morgan GJ, Houlston RS.

Blood Cancer J. 2017 Jun 16;7(6):e573. doi: 10.1038/bcj.2017.48. No abstract available.

38.

Prediction of outcome in newly diagnosed myeloma: a meta-analysis of the molecular profiles of 1905 trial patients.

Shah V, Sherborne AL, Walker BA, Johnson DC, Boyle EM, Ellis S, Begum DB, Proszek PZ, Jones JR, Pawlyn C, Savola S, Jenner MW, Drayson MT, Owen RG, Houlston RS, Cairns DA, Gregory WM, Cook G, Davies FE, Jackson GH, Morgan GJ, Kaiser MF.

Leukemia. 2018 Jan;32(1):102-110. doi: 10.1038/leu.2017.179. Epub 2017 Jun 6.

39.

The level of deletion 17p and bi-allelic inactivation of TP53 has a significant impact on clinical outcome in multiple myeloma.

Thanendrarajan S, Tian E, Qu P, Mathur P, Schinke C, van Rhee F, Zangari M, Rasche L, Weinhold N, Alapat D, Bellamy W, Ashby C, Mattox S, Epstein J, Yaccoby S, Barlogie B, Hoering A, Bauer M, Walker BA, Davies FE, Morgan GJ.

Haematologica. 2017 Sep;102(9):e364-e367. doi: 10.3324/haematol.2017.168872. Epub 2017 May 26. No abstract available.

40.

The spectrum of somatic mutations in monoclonal gammopathy of undetermined significance indicates a less complex genomic landscape than that in multiple myeloma.

Mikulasova A, Wardell CP, Murison A, Boyle EM, Jackson GH, Smetana J, Kufova Z, Pour L, Sandecka V, Almasi M, Vsianska P, Gregora E, Kuglik P, Hajek R, Davies FE, Morgan GJ, Walker BA.

Haematologica. 2017 Sep;102(9):1617-1625. doi: 10.3324/haematol.2017.163766. Epub 2017 May 26.

41.

The role of next generation sequencing in infection prevention in human parainfluenza virus 3 infections in immunocompromised patients.

Kothari A, Burgess MJ, Crescencio JCR, Kennedy JL, Denson JL, Schwalm KC, Stoner AN, Kincaid JC, Davies FE, Dinwiddie DL.

J Clin Virol. 2017 Jul;92:53-55. doi: 10.1016/j.jcv.2017.05.010. Epub 2017 May 12.

42.

The prognostic value of the depth of response in multiple myeloma depends on the time of assessment, risk status and molecular subtype.

Schinke C, Hoering A, Wang H, Carlton V, Thanandrarajan S, Deshpande S, Patel P, Molnar G, Susanibar S, Mohan M, Mathur P, Radhakrishnan M, Hoque S, Jo Kamimoto J, Grazziutti M, van Rhee F, Zangari M, Insuasti-Beltran G, Alapat D, Post G, Yaccoby S, Epstein J, Rasche L, Johnson S, Moorhead M, Willis T, Barlogie B, Walker B, Weinhold N, Davies FE, Morgan GJ.

Haematologica. 2017 Aug;102(8):e313-e316. doi: 10.3324/haematol.2017.165217. Epub 2017 May 18. No abstract available.

43.

Low expression of hexokinase-2 is associated with false-negative FDG-positron emission tomography in multiple myeloma.

Rasche L, Angtuaco E, McDonald JE, Buros A, Stein C, Pawlyn C, Thanendrarajan S, Schinke C, Samant R, Yaccoby S, Walker BA, Epstein J, Zangari M, van Rhee F, Meissner T, Goldschmidt H, Hemminki K, Houlston R, Barlogie B, Davies FE, Morgan GJ, Weinhold N.

Blood. 2017 Jul 6;130(1):30-34. doi: 10.1182/blood-2017-03-774422. Epub 2017 Apr 21.

44.

Immunologic approaches for the treatment of multiple myeloma.

Rasche L, Weinhold N, Morgan GJ, van Rhee F, Davies FE.

Cancer Treat Rev. 2017 Apr;55:190-199. doi: 10.1016/j.ctrv.2017.03.010. Epub 2017 Apr 6. Review.

45.

The Role of Minimal Residual Disease Testing in Myeloma Treatment Selection and Drug Development: Current Value and Future Applications.

Anderson KC, Auclair D, Kelloff GJ, Sigman CC, Avet-Loiseau H, Farrell AT, Gormley NJ, Kumar SK, Landgren O, Munshi NC, Cavo M, Davies FE, Di Bacco A, Dickey JS, Gutman SI, Higley HR, Hussein MA, Jessup JM, Kirsch IR, Little RF, Loberg RD, Lohr JG, Mukundan L, Omel JL, Pugh TJ, Reaman GH, Robbins MD, Sasser AK, Valente N, Zamagni E.

Clin Cancer Res. 2017 Aug 1;23(15):3980-3993. doi: 10.1158/1078-0432.CCR-16-2895. Epub 2017 Apr 20.

46.

The varied distribution and impact of RAS codon and other key DNA alterations across the translocation cyclin D subgroups in multiple myeloma.

Stein CK, Pawlyn C, Chavan S, Rasche L, Weinhold N, Corken A, Buros A, Sonneveld P, Jackson GH, Landgren O, Mughal T, He J, Barlogie B, Bergsagel PL, Davies FE, Walker BA, Morgan GJ.

Oncotarget. 2017 Apr 25;8(17):27854-27867. doi: 10.18632/oncotarget.15718.

47.

Search for rare protein altering variants influencing susceptibility to multiple myeloma.

Scales M, Chubb D, Dobbins SE, Johnson DC, Li N, Sternberg MJ, Weinhold N, Stein C, Jackson G, Davies FE, Walker BA, Wardell CP, Houlston RS, Morgan GJ.

Oncotarget. 2017 May 30;8(22):36203-36210. doi: 10.18632/oncotarget.15874.

48.

Overexpression of EZH2 in multiple myeloma is associated with poor prognosis and dysregulation of cell cycle control.

Pawlyn C, Bright MD, Buros AF, Stein CK, Walters Z, Aronson LI, Mirabella F, Jones JR, Kaiser MF, Walker BA, Jackson GH, Clarke PA, Bergsagel PL, Workman P, Chesi M, Morgan GJ, Davies FE.

Blood Cancer J. 2017 Mar 31;7(3):e549. doi: 10.1038/bcj.2017.27.

49.

Update on the optimal use of bortezomib in the treatment of multiple myeloma.

Mohan M, Matin A, Davies FE.

Cancer Manag Res. 2017 Mar 2;9:51-63. doi: 10.2147/CMAR.S105163. eCollection 2017. Review.

50.

Extensive Remineralization of Large Pelvic Lytic Lesions Following Total Therapy Treatment in Patients With Multiple Myeloma.

Mohan M, Samant RS, Yoon D, Buros AF, Branca A, Montgomery CO, Nicholas R, Suva LJ, Morello R, Thanendrarajan S, Schinke C, Yaccoby S, van Rhee F, Davies FE, Morgan GJ, Zangari M.

J Bone Miner Res. 2017 Jun;32(6):1261-1266. doi: 10.1002/jbmr.3111. Epub 2017 Mar 27.

Supplemental Content

Loading ...
Support Center